

# Nishida Naoshi

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6755519/nishida-naoshi-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

64  
papers

1,980  
citations

25  
h-index

43  
g-index

72  
ext. papers

2,482  
ext. citations

6  
avg, IF

5.3  
L-index

#	Paper	IF	Citations
64	Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. <i>Hepatology</i> , <b>2008</b> , 47, 908-18	11.2	211
63	Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review. <i>Current Genomics</i> , <b>2011</b> , 12, 130-7	2.6	148
62	Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma. <i>Liver Cancer</i> , <b>2015</b> , 4, 253-62	9.1	130
61	Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma. <i>Hepatology</i> , <b>2012</b> , 56, 994-1003	11.2	110
60	Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria). <i>Digestive Diseases</i> , <b>2015</b> , 33, 751-8	3.2	103
59	Serum miR-21, miR-29a, and miR-125b Are Promising Biomarkers for the Early Detection of Colorectal Neoplasia. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 4234-42	12.9	101
58	Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study. <i>Cancers</i> , <b>2019</b> , 11,	6.6	92
57	Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study. <i>Cancers</i> , <b>2019</b> , 11,	6.6	71
56	Immunological Microenvironment of Hepatocellular Carcinoma and Its Clinical Implication. <i>Oncology</i> , <b>2017</b> , 92 Suppl 1, 40-49	3.6	69
55	High copy amplification of the Aurora-A gene is associated with chromosomal instability phenotype in human colorectal cancers. <i>Cancer Biology and Therapy</i> , <b>2007</b> , 6, 525-33	4.6	66
54	Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma. <i>Digestive Diseases</i> , <b>2015</b> , 33, 771-9	3.2	62
53	Recent advancements in comprehensive genetic analyses for human hepatocellular carcinoma. <i>Oncology</i> , <b>2013</b> , 84 Suppl 1, 93-7	3.6	52
52	Extensive methylation is associated with beta-catenin mutations in hepatocellular carcinoma: evidence for two distinct pathways of human hepatocarcinogenesis. <i>Cancer Research</i> , <b>2007</b> , 67, 4586-94	10.1	50
51	Oncogenic Signal and Tumor Microenvironment in Hepatocellular Carcinoma. <i>Oncology</i> , <b>2017</b> , 93 Suppl 1, 160-164	3.6	42
50	MicroRNAs for the Prediction of Early Response to Sorafenib Treatment in Human Hepatocellular Carcinoma. <i>Liver Cancer</i> , <b>2017</b> , 6, 113-125	9.1	41
49	Immune checkpoint blockade for the treatment of human hepatocellular carcinoma. <i>Hepatology Research</i> , <b>2018</b> , 48, 622-634	5.1	38
48	Alteration of Epigenetic Profile in Human Hepatocellular Carcinoma and Its Clinical Implications. <i>Liver Cancer</i> , <b>2014</b> , 3, 417-27	9.1	33

47	Comprehensive allelotyping of well-differentiated human hepatocellular carcinoma with semiquantitative determination of chromosomal gain or loss. <i>Genes Chromosomes and Cancer</i> , <b>2002</b> , 35, 329-39	5	33
46	Unique features associated with hepatic oxidative DNA damage and DNA methylation in non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2016</b> , 31, 1646-53	4	31
45	Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2. <i>Digestive Diseases</i> , <b>2017</b> , 35, 589-597	3.2	27
44	Unique association between global DNA hypomethylation and chromosomal alterations in human hepatocellular carcinoma. <i>PLoS ONE</i> , <b>2013</b> , 8, e72312	3.7	27
43	Rescue EUS-guided intrahepatic biliary drainage for malignant hilar biliary stricture after failed transpapillary re-intervention. <i>Surgical Endoscopy and Other Interventional Techniques</i> , <b>2017</b> , 31, 4764-4772	5.3	26
42	Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma. <i>Cancer Science</i> , <b>2017</b> , 108, 1996-2003	6.9	26
41	Alteration of the p14(ARF) gene and p53 status in human hepatocellular carcinomas. <i>Journal of Gastroenterology</i> , <b>2004</b> , 39, 355-61	6.9	25
40	Liver damage related to immune checkpoint inhibitors. <i>Hepatology International</i> , <b>2019</b> , 13, 248-252	8.8	25
39	Discrete breakpoint mapping and shortest region of overlap of chromosome arm 1q gain and 1p loss in human hepatocellular carcinoma detected by semiquantitative microsatellite analysis. <i>Genes Chromosomes and Cancer</i> , <b>2005</b> , 42, 34-43	5	23
38	Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B. <i>Journal of Medical Virology</i> , <b>2019</b> , 91, 1804-1810	19.7	21
37	Prognostic impact of multiple allelic losses on metastatic recurrence in hepatocellular carcinoma after curative resection. <i>Oncology</i> , <b>2002</b> , 62, 141-8	3.6	20
36	Genome-wide profiling of DNA methylation and tumor progression in human hepatocellular carcinoma. <i>Digestive Diseases</i> , <b>2014</b> , 32, 658-63	3.2	19
35	Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B. <i>Journal of Medical Virology</i> , <b>2013</b> , 85, 987-95	19.7	19
34	Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody. <i>Liver Cancer</i> , <b>2021</b> , 10, 380-393	9.1	17
33	Validation of a Modified Substaging System (Kinki Criteria) for Patients with Intermediate-Stage Hepatocellular Carcinoma. <i>Oncology</i> , <b>2015</b> , 89 Suppl 2, 47-52	3.6	16
32	Molecular Scoring of Hepatocellular Carcinoma for Predicting Metastatic Recurrence and Requirements of Systemic Chemotherapy. <i>Cancers</i> , <b>2018</b> , 10,	6.6	15
31	Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1. <i>Liver Cancer</i> , <b>2020</b> , 9, 426-439	9.1	14
30	Clinical Significance of Epigenetic Alterations in Human Hepatocellular Carcinoma and Its Association with Genetic Mutations. <i>Digestive Diseases</i> , <b>2016</b> , 34, 708-713	3.2	14

29	Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma. <i>Cancers</i> , <b>2020</b> , 12,	6.6	13
28	Current status and perspectives for computer-aided ultrasonic diagnosis of liver lesions using deep learning technology. <i>Hepatology International</i> , <b>2019</b> , 13, 416-421	8.8	12
27	Identification of epigenetically inactivated genes in human hepatocellular carcinoma by integrative analyses of methylation profiling and pharmacological unmasking. <i>Digestive Diseases</i> , <b>2014</b> , 32, 740-6	3.2	12
26	Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD-1/PD-L1 Checkpoint Blockade. <i>Cancers</i> , <b>2020</b> , 12,	6.6	12
25	Role of Oncogenic Pathways on the Cancer Immunosuppressive Microenvironment and Its Clinical Implications in Hepatocellular Carcinoma. <i>Cancers</i> , <b>2021</b> , 13,	6.6	12
24	Serum Levels of $\alpha$ Fetoprotein Increased More Than 10 Years Before Detection of Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 162-170.e4	6.9	10
23	Role of Immune Checkpoint Blockade in the Treatment for Human Hepatocellular Carcinoma. <i>Digestive Diseases</i> , <b>2017</b> , 35, 618-622	3.2	8
22	Impaired expression of ATP-binding cassette transporter G2 and liver damage in erythropoietic protoporphyria. <i>Hepatology</i> , <b>2015</b> , 62, 1638-9	11.2	8
21	Efficacy of a modified double-guidewire technique using an uneven double lumen cannula (uneven method) in patients with surgically altered gastrointestinal anatomy (with video). <i>Surgical Endoscopy and Other Interventional Techniques</i> , <b>2020</b> , 34, 1432-1441	5.2	8
20	Value of additional endoscopic ultrasonography for surveillance after surgical removal of intraductal papillary mucinous neoplasms. <i>Digestive Endoscopy</i> , <b>2018</b> , 30, 659-666	3.7	7
19	Hepatic DNA Methylation Is Affected by Hepatocellular Carcinoma Risk in Patients with and without Hepatitis Virus. <i>Digestive Diseases</i> , <b>2015</b> , 33, 745-50	3.2	6
18	Artificial Intelligence in Medical Imaging and Its Application in Sonography for the Management of Liver Tumor. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 594580	5.3	5
17	Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma treated with Systemic Therapies.. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	5
16	Impact of Tumor Factors on Survival in Patients with Hepatocellular Carcinoma Classified Based on Kinki Criteria Stage B2. <i>Digestive Diseases</i> , <b>2017</b> , 35, 583-588	3.2	4
15	Monoethanolamine Oleate Sclerotherapy for Polycystic Liver Disease. <i>Digestive Diseases</i> , <b>2016</b> , 34, 654-658	3.2	4
14	Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma.. <i>Liver Cancer</i> , <b>2021</b> , 10, 615-628	9.1	4
13	Stress Response Protein RBM3 Promotes the Development of Colitis-associated Cancer. <i>Inflammatory Bowel Diseases</i> , <b>2017</b> , 23, 66-74	4.5	3
12	Gender differences in the livers of patients with hepatocellular carcinoma and chronic hepatitis C infection. <i>Digestive Diseases</i> , <b>2012</b> , 30, 547-53	3.2	3

11	Computer aided diagnosis system developed for ultrasound diagnosis of liver lesions using deep learning <b>2019</b> ,		3
10	Optimal cropping for input images used in a convolutional neural network for ultrasonic diagnosis of liver tumors. <i>Japanese Journal of Applied Physics</i> , <b>2020</b> , 59, SKKE09	1.4	2
9	Contribution of C1485T mutation in the HBx gene to human and murine hepatocarcinogenesis. <i>Scientific Reports</i> , <b>2017</b> , 7, 10440	4.9	2
8	Accumulation of Genetic and Epigenetic Alterations in the Background Liver and Emergence of Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease. <i>Cells</i> , <b>2021</b> , 10,	7.9	2
7	Clinicopathological analysis of hepatic immune-related adverse events in comparison with autoimmune hepatitis and graft-versus host disease. <i>Scientific Reports</i> , <b>2021</b> , 11, 9242	4.9	2
6	Current Perspectives on the Immunosuppressive Niche and Role of Fibrosis in Hepatocellular Carcinoma and the Development of Antitumor Immunity. <i>Journal of Histochemistry and Cytochemistry</i> , <b>2021</b> , 221554211056853	3.4	1
5	Cystic duct antegrade stenting for cholangitis after the long-term deployment of lumen-apposing metal stents for calculous cholecystitis. <i>Endoscopic Ultrasound</i> , <b>2018</b> , 7, 349-350	3.6	1
4	Artificial intelligence (AI) models for the ultrasonographic diagnosis of liver tumors and comparison of diagnostic accuracies between AI and human experts.. <i>Journal of Gastroenterology</i> , <b>2022</b> , 57, 309	6.9	1
3	Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma.. <i>Liver Cancer</i> , <b>2021</b> , 10, 583-592	9.1	0
2	Improved Tumor Response to Lenvatinib Re-Treatment after Failure of Immune Checkpoint Inhibitors in a Patient with Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , <b>2021</b> , 10, 535-538	9.1	0
1	Role of phlebotomy in the treatment of liver damage related to erythropoietic porphyria.. <i>Scientific Reports</i> , <b>2022</b> , 12, 6100	4.9	0